Ewa Grzybowska

Ewa Grzybowska

orcid

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2010 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
TBTomasz Byrski
Tomasz Byrski
JGJacek Gronwald
Jacek Gronwald
THTomasz Huzarski
Tomasz Huzarski
EGEwa Grzybowska
Ewa Grzybowska
MBMagdalena Budryk
Magdalena Budryk
SNSteven Narod
Steven Narod
Purpose: To estimate the rate of pathologic complete response (pCR) to neoadjuvant chemotherapy in BRCA1 mutation carriers according to chemotherapy regimen. Patients and Methods: From a registry of 6,903 patients, we identified 102 women who carried a BRCA1 founder mutation and who had been treated for breast cancer with neoadjuvant chemotherapy. Pathologic complete response was evaluated using standard criteria. Results: Twenty-four (24%) of the 102 BRCA1 mutation carriers experienced a pCR. The response rate varied widely with treatment: a pCR was observed in one (7%) of 14 women treated with cyclophosphamide, methotrexate, and fluorouracil (CMF); in two (8%) of 25 women treated with doxorubicin and docetaxel (AT); in 11 (22%) of 51 women treated with doxorubicin and cyclophosphamide (AC) or fluorouracil, doxorubicin, and cyclophosphamide (FAC), and in 10 (83%) of 12 women treated with cisplatin. Conclusion: A low rate of pCR was observed in women with breast cancer and a BRCA1 mutation who were treated with AT or CMF. A high rate of pCR was seen after treatment with cisplatin. An intermediate rate of PCR was associated with AC or FAC. The relative benefits of AC and platinum therapy need to be confirmed through follow-up of this and other cohorts.

1 June 2000 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
BGB. Górski
B. Górski
TBTomasz Byrski
Tomasz Byrski
THTomasz Huzarski
Tomasz Huzarski
AJAnna Jakubowska
Anna Jakubowska
JMJ. Menkiszak
J. Menkiszak
JLJ. Lubiński
J. Lubiński

15 May 2005 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
QJQianren Jin
Qianren Jin
KHKari Hemminki
Kari Hemminki
KEKerstin Enquist
Kerstin Enquist
PLPer Lenner
Per Lenner
EGEwa Grzybowska
Ewa Grzybowska
AFAsta Försti
Asta Försti
Purpose: Angiogenesis is a necessary step in tumor growth and metastasis. Vascular endothelial growth factor (VEGF) is a major mediator of breast cancer angiogenesis. Therefore, we investigated the association of polymorphisms in the VEGF gene with breast cancer risk and prognostic characteristics of the tumors in a large case-control study. Experimental Design: We examined three polymorphisms in the VEGF gene (−2578C/A, −1154G/A, and +936C/T) in 571 familial breast cancer cases from Poland and Germany and −2578C/A, −634G/C, and +936C/T polymorphisms in 974 unselected breast cancer cases from Sweden together with ethnically and geographically selected controls. Results: None of the polymorphisms or any haplotype was significantly associated with either familial or unselected breast cancers. Our study suggests that the +936C/T polymorphism is unlikely to be associated with breast cancer. We also analyzed the unselected cases for genotypes or haplotypes that associated with tumor characteristics. The −634CC genotype and the −2578/−634 CC haplotype were significantly associated with high tumor aggressiveness (large tumor size and high histologic grade, P < 0.01) and the −2578AA genotype and the −2578/−634 AG haplotype with low histologic grade tumors (P = 0.04). The genotypes and haplotypes were not related with other tumor characteristics such as regional or distant metastasis, stage at diagnosis, or estrogen or progesterone receptor status. Conclusions: Although none of the polymorphisms studied in the VEGF gene was found to influence susceptibility to breast cancer significantly, some of the VEGF genotypes and haplotypes may influence tumor growth through an altered expression of VEGF and tumor angiogenesis.

15 March 2004 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
BGBohdan Górski
Bohdan Górski
AJAnna Jakubowska
Anna Jakubowska
THTomasz Huzarski
Tomasz Huzarski
TBTomasz Byrski
Tomasz Byrski
JGJacek Gronwald
Jacek Gronwald
JLJan Lubiński
Jan Lubiński
Three mutations in BRCA1 (5382insC, C61G and 4153delA) are common in Poland and account for the majority of mutations identified to date in Polish breast and breast–ovarian cancer families. It is not known, however, to what extent these 3 founder mutations account for all of the BRCA mutations distributed throughout the country. This question has important implications for health policy and the design of epidemiologic studies. To establish the relative contributions of founder and nonfounder BRCA mutations, we established the entire spectrum of BRCA1 and BRCA2 mutations in a large set of breast–ovarian cancer families with origins in all regions of Poland. We sequenced the entire coding regions of the BRCA1 and BRCA2 genes in 100 Polish families with 3 or more cases of breast cancer and in 100 families with cases of both breast and ovarian cancer. A mutation in BRCA1 or BRCA2 was detected in 66% of breast cancer families and in 63% of breast–ovarian cancer families. Of 129 mutations, 122 (94.6%) were in BRCA1 and 7 (5.4%) were in BRCA2. Of the 122 families with BRCA1 mutations, 119 (97.5%) had a recurrent mutation (i.e., one that was seen in at least 2 families). In particular, 111 families (91.0%) carried one of the 3 common founder mutations. The mutation spectrum was not different between families with and without ovarian cancer. These findings suggest that a rapid and inexpensive assay directed at identifying the 3 common founder mutations will have a sensitivity of 86% compared to a much more costly and labor‐intensive full‐sequence analysis of both genes. This rapid test will facilitate large‐scale national epidemiologic and clinical studies of hereditary breast cancer, potentially including studies of chemoprevention.

10 May 2007 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
TBTomasz Byrski
Tomasz Byrski
JGJ. Gronwald
J. Gronwald
THTomasz Huzarski
Tomasz Huzarski
EGEwa Grzybowska
Ewa Grzybowska
MBM. Budryk
M. Budryk
TCthe Polish Hereditary Breast Cancer Consortium
the Polish Hereditary Breast Cancer Consortium

1 January 2014 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
KLKatarzyna Marta Lisowska
Katarzyna Marta Lisowska
MOMagdalena Olbryt
Magdalena Olbryt
VDVolha Dudaladava
Volha Dudaladava
JPJolanta Pamuła-Piłat
Jolanta Pamuła-Piłat
KKKatarzyna Kujawa
Katarzyna Kujawa
JKJolanta Kupryjańczyk
Jolanta Kupryjańczyk
The introduction of microarray techniques to cancer research brought great expectations for finding biomarkers that would improve patients treatment; however, the results of such studies are poorly reproducible, and critical analyses of these methods are rare. In this study we examined gene expression in 97 ovarian cancer samples. Validation of results by quantitative RT-PCR was performed also on 30 additional ovarian cancer samples. We carried out a number of systematic analyses in relation to several defined clinicopathological features. The main goal of our study was to delineate the molecular background of ovarian cancer chemoresistance and find biomarkers suitable for prediction of patients prognosis. Histological tumor type was the major source of variability in genes expression, except for serous and undifferentiated tumors that showed nearly identical profiles. Analysis of clinical endpoints (tumor response to chemotherapy, overall survival, disease-free survival, DFS) brought results that were not confirmed by validation either on the same group or on the independent group of patients. CLASP1 was the only gene that was found as important for DFS in the independent group, while in the preceding experiments it showed associations with other clinical endpoints and with BRCA1 gene mutation; thus, it may be worth of further testing. Our results confirm that histological tumor type is a strong confounding factor and gene expression studies of ovarian carcinomas should be performed on histologically homogeneous groups. Relatively small and unequal patients groups, may be a reason of poor reproducibility of statistical results, as well as the fact that the patients were treated with different chemotherapies. In addition, clinical endpoints may depend on subtle changes in many alternative molecular pathways, and this may be difficult to demonstrate by the methods applied. Also, arbitrarily performed division of samples may not reflect their true biological diversity